Furthermore, an increase in PD-L1 gene copy number may serve as a novel prognostic and potential predictive biomarker for anti-PD-1/PD-L1 therapy in locally advanced cervical cancer (49). This evidence concerns the gene CD274 and cervical carcinoma.